Archeus Technologies advances prostate cancer research with new collaboration and FDA clearance

We’re thrilled to share the latest milestone from our portfolio company, Archeus Technologies, as they announce a new collaboration with the Wisconsin Alumni Research Foundation (WARF) to advance a novel radiopharmaceutical for prostate cancer. In a major step forward, the FDA has cleared the Investigational New Drug (IND) application for ART-101, paving the way for a Phase 1 clinical trial in men with prostate cancer later this year.

ART-101 was discovered and developed by Reinier Hernandez, PhD, at the Advanced Radiotheranostics Lab at the University of Wisconsin School of Medicine and Public Health.

Elizabeth Hagerman, Executive Director of the Isthmus Project and Chief Innovation Officer at UW Health, commented:

“We continue to be impressed by the progress Archeus is making toward transforming cancer treatment. This collaboration and the recent FDA clearance are further demonstrations of their strategic vision and the promise of their approach to developing innovative radiopharmaceuticals.”

Press Releases

• Archeus Technologies and Wisconsin Alumni Research Foundation partner to advance radiopharmaceutical therapy ART-101 into clinical development for prostate cancer
• Archeus Technologies receives FDA clearance of investigational new drug application for ART-101 in development for the treatment of prostate cancer